Rakshit Drugs Private Limited – FDA 483, Nov 22, 2024
An FDA inspection of Rakshit Drugs Private Limited in Anakapalli, India, an API and intermediate manufacturer, revealed significant deficiencies in quality control. Observations included inadequate equipment cleaning procedures, insufficient equipment qualification, flawed out-of-specification investigations, and unsecured computerized system data backups. Additionally, improper microbiological water quality analysis was noted, indicating systemic issues in ensuring product quality and data integrity.
ID · 00973d3f-5378-43ec-bda4-4258badebbce
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.